TherapeuticsMD Inc (TXMD)

4.99
AMEX : Health Care
Prev Close 4.99
Day Low/High 0.00 / 0.00
52 Wk Low/High 4.39 / 9.29
Avg Volume 3.12M
Exchange AMEX
Shares Outstanding 197.52M
Market Cap 965.89M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.

SHAREHOLDER ALERT: Goldberg Law PC Announces The Filing Of A Securities Class Action Lawsuit Against TherapeuticsMD, Inc.

SHAREHOLDER ALERT: Goldberg Law PC Announces The Filing Of A Securities Class Action Lawsuit Against TherapeuticsMD, Inc.

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against TherapeuticsMD, Inc.

Downgrading TherapeuticsMD

Company commentary this morning adds layer of uncertainty, which warrants being extra cautious.

TherapeuticsMD Provides Additional Information On TX-004HR Regulatory Update

TherapeuticsMD Provides Additional Information On TX-004HR Regulatory Update

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that, based on continued correspondence with the U.

Exiting a Financial Position

We are selling our holdings in Synovus Financial on today's strength. Plus, an update on TherapeuticsMD.

Stocks Under $10 Weekly Summary

We added a new name to the portfolio as the market took a breather in a shortened trading week.

TherapeuticsMD Falls More, but We're Keeping It for Now

We'll wait to see how firm deals with FDA letter.

Stocks Under $10 Weekly Summary

Chris Versace runs down the portfolio.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving TherapeuticsMD, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving TherapeuticsMD, Inc.

Levi & Korsinsky announces it has commenced an investigation of TherapeuticsMD, Inc.

TherapeuticsMD Whacked on FDA News

The company received a letter from the Food and Drug Administration involving deficiencies of an application for a key drug candidate.

TherapeuticsMD Provides TX-004HR Regulatory Update

TherapeuticsMD Provides TX-004HR Regulatory Update

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that, on April 7, 2017, the Company received a letter from the U.

Penn National Gaming, Wynn Resorts: 'Mad Money' Lightning Round

Penn National Gaming, Wynn Resorts: 'Mad Money' Lightning Round

Jim Cramer thinks Penn National Gaming and Wynn Resorts could be a good deal for investors.

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)

In the short term, all that matters in the market is what someone is willing to pay, says Jim Cramer.

Drug Trial News Lifts TherapeuticsMD

Treatments aimed at aspects of menopause.

TherapeuticsMD Presents Positive Phase 3 Data In Two Presentations For TX-001HR At ENDO 2017

TherapeuticsMD Presents Positive Phase 3 Data In Two Presentations For TX-001HR At ENDO 2017

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that data on TX-001HR, an investigational bio-identical hormone therapy combination of 17ß-estradiol and progesterone in...

Stocks Under $10 Weekly Summary

We beat the benchmark Russell 2000 for the quarter, and we await a busy week on the economic front.

Huntington Bancshares Is on Our Radar

Plus 2 health-care positions have a good day.

Stocks Under $10 Weekly Summary

We are keeping an eye on rate-sensitive names for possible buying opportunities, as stocks fell around 1.5% this week.

Interesting TXMD Put And Call Options For May 19th

Interesting TXMD Put And Call Options For May 19th

Investors in TherapeuticsMD, Inc. saw new options begin trading this week, for the May 19th expiration.

Stocks Under $10 Weekly Summary

We picked up more Abraxas Petroleum on weakness, while the market rebounded slightly after the FOMC announced the anticipated quarter-point rate hike.

TherapeuticsMD Announces Presentation At The Oppenheimer 27th Annual Healthcare Conference On March 22

TherapeuticsMD Announces Presentation At The Oppenheimer 27th Annual Healthcare Conference On March 22

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company's CEO Robert Finizio will present at the Oppenheimer 27 th Annual Healthcare Conference in New York on March...

Stocks Under $10 Weekly Summary

We bulked up on Abraxas Petroleum and Yamana Gold on weakness, as the markets pulled back and investors positioned for next week’s FOMC meeting.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Finding the stocks that have changed direction.

TherapeuticsMD Announces Presentation At Cowen And Company 37th Annual Healthcare Conference On March 7

TherapeuticsMD Announces Presentation At Cowen And Company 37th Annual Healthcare Conference On March 7

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company's CEO Robert Finizio will present at the Cowen and Company 37 th Annual Healthcare Conference in Boston March...

Stocks Under $10 Weekly Summary

We booked some profits in Huntington Bancshares and Builders FirstSource, while markets digested the likelihood of a March rate hike.

Stocks Under $10 Weekly Summary

We opened a new position in Abraxas Petroleum on its above-average growth potential, as stocks faced selling pressure this week.

TherapeuticsMD Rating Reaffirmed After Earnings

The timeline for its two lead hormone therapy treatments remains on pace.

TherapeuticsMD Announces Fourth Quarter And Full-Year 2016 Financial Results

TherapeuticsMD Announces Fourth Quarter And Full-Year 2016 Financial Results

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its fourth quarter and full-year financial results for 2016.